Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6

Cell Death and Differentiation

Volumn 17, Issue 1, 2010, Pages 158-169

  Giaime, E ^a   Sunyach, C ^a   Druon, C ^a   Scarzello, S ^a   Robert, G ^b   Grosso, S ^b   Auberger, P ^b   Goldberg, M S ^c,f   Shen, J ^c   Heutink, P ^d   Pouyssegur J ^e   Pages G ^e   Checler, F ^a   Da Costa, C Alves ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

autosomal recessive cases; caspase 6; DJ1; mutations; p53; Parkinson's diseased

Indexed keywords

CASPASE 6; DJ 1 PROTEIN; PROTEIN P53; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROCESSING; PROTEIN STABILITY; TRANSCRIPTION REGULATION; AMINO ACID SUBSTITUTION; ANIMAL; APOPTOSIS; BRAIN; CELL CULTURE; GENETICS; METABOLISM; MOUSE; MUTATION; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; BRAIN; CASPASE 6; CELLS, CULTURED; DIMERIZATION; DOWN-REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; ONCOGENE PROTEINS; PARKINSON DISEASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77449156069     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.116     Document Type: Article

References (57)

1. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18: 363-369. (Pubitemid 41104797)
2. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 2003; 54: 283-286. (Pubitemid 37072030)
3. Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 2004; 62: 389-394. (Pubitemid 38200848)
4. Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004; 127 (Part 2): 420-430. (Pubitemid 38160326)
5. Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun 2004; 320: 389-397. (Pubitemid 38798879)
6. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonismlinked gene DJ-1. Neuron 2005; 45: 489-496. (Pubitemid 40249861)
7. Lee SJ, Kim SJ, Kim IK, Ko J, Jeong CS, Kim GH et al. Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. J Biol Chem 2003; 278: 44552-44559. (Pubitemid 37377208)
8. Hod Y, Pentyala SN, Whyard TC, El-Maghrabi MR. Identification and characterization of a novel protein that regulates RNA-protein interaction. J Cell Biochem 1999; 72: 435-444. (Pubitemid 29047405)
9. Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM, Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 2001; 276: 37556-37563.
10. Palvimo JJ. PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem Soc Trans 2007; 35 (Part 6): 1405-1408.
11. Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, Maita C et al. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ 2006; 13: 96-108.
12. Kinumi T, Kimata J, Taira T, Ariga H, Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 317: 722-728. (Pubitemid 38481432)
13. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic aciddriven mitochondrial localization. Proc Natl Acad Sci USA 2004; 101: 9103-9108. (Pubitemid 38781618)
14. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5: 213-218. (Pubitemid 38401204)
15. Moore DJ, Zhang L, Dawson TM, Dawson VL. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homooligomerization. J Neurochem 2003; 87: 1558-1567. (Pubitemid 38020589)
16. Blum D, Torch S, Lambeng N, Nissou M-F, Benabid A-L, Sadoul R et al. Molecular pathways involved in the neurotoxicity of 6OH-DOPA and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65: 135-172. (Pubitemid 32524182)
17. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-347. (Pubitemid 24300618)
18. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000; 14: 2358-2365.
19. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 36031-36034.
20. Brooks CL, Gu W. Ubiquitination, phosphorilation and acetylation: the molecular basis for p53 regulation. Curr Op Cell Biol 2003; 15: 1-8.
21. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598-11603. (Pubitemid 32928774)
22. Ogawara Y, Kishishita S, Obata T, Ysazawa Y, Suzuki T, Tanaka K et al. Akt enhances mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 21843-21850. (Pubitemid 34952337)
23. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284. (Pubitemid 47125967)
24. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 2005; 24: 6719-6728. (Pubitemid 41486802)
25. Milne D, Kampanis P, Nicol S, Dias S, Campbell DG, Fuller-Pace F et al. A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein. FEBS Lett 2004; 577: 270-276. (Pubitemid 39452397)
26. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
27. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89: 7262-7266.
28. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004; 2: e362.
29. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704. (Pubitemid 24036020)
30. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 2003; 278: 36588-36595. (Pubitemid 37139990)
31. Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspase inhibitors. Trends Biochem Sci 1997; 22: 388-393. (Pubitemid 27438202)
32. Alves da Costa C. DJ-1 a new comer in Parkinson's disease pathology. Curr Mol Med 2007; 7: 650-657.
33. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl 1995; 46: 297-314. (Pubitemid 26043238)
34. Bretaud S, Allen C, Ingham PW, Bandmann O. p53-dependent neuronal cell death in a DJ- 1-deficient zebrafish model of Parkinson's disease. J Neurochem 2007; 100: 1626-1635. (Pubitemid 46376201)
35. Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L et al. Inactivation of Drosophila DJ- 1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 2005; 102: 13670-13675. (Pubitemid 41420906)
36. Deffie A, Wu H, Reinke V, Lozano G. The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 1993; 13: 3415-3423. (Pubitemid 23157278)
37. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999; 22: 110-114. (Pubitemid 29214817)
38. Giaime E, Sunyach C, Herrant M, Grosso S, Auberger P, McLean P et al. Caspase 3- derived C-terminal product of synphilin-1 displays anti-apoptotic function via modulation of the p53-dependent cell death pathway. J Biol Chem 2006; 281: 11515-11522. (Pubitemid 43855407)
39. Duan W, Zhu X, Ladenheim B, Qian-Sheng Y, Guo Z, Oyler J et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606. (Pubitemid 35246863)
40. Blum D, Wu Y, Nissou M-F, Arnaud S, Benabid A-L, Verna J-M. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res 1997; 751: 139-142. (Pubitemid 27122145)
41. Kahns S, Kalai M, Jakobsen LD, Clark BF, Vandenabeele P, Jensen PH. Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem 2003; 278: 23376-23380. (Pubitemid 36830153)
42. Dong Z, Ferger B, Paterna J-C, Vogel D, Furler S, Osinde M et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target CDC-rel1. Proc Natl Acad Sci USA 2003; 100: 12438-12443. (Pubitemid 37271578)
43. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuronselective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003; 37: 911-924. (Pubitemid 36398298)
44. Henn IH, Gostner JM, Lackner P, Tatzelt J, Winklhofer KF. Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem 2005; 92: 114-122. (Pubitemid 40193514)
45. Darios F, Corti O, Lücking CB, Hampe C, Miuriel M-P, Abbas N et al. Parkin prevents mitochondrial swelling and cytochrome C release in mitochondria dependent cell death. Hum Mol Gen 2003; 12: 517-526. (Pubitemid 36305590)
46. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659. (Pubitemid 27513656)
47. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999; 286: 1374-1377.
48. Sunyach C, Cisse MA, da Costa CA, Vincent B, Checler F. The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation. J Biol Chem 2007; 282: 1956-1963. (Pubitemid 47076732)
49. Alves Da Costa C, Paitel E, Vincent B, Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J Biol Chem 2002; 277: 50980-50984. (Pubitemid 36042267)
50. Alves da Costa C, Dunys J, Brau F, Wilk S, Cappai R, Checler F. 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J Biol Chem 2006; 281: 9824-9831. (Pubitemid 43864701)
51. Shang H, Lang D, Jean-Marc B, Kaelin-Lang A. Localization of DJ-1 mRNA in the mouse brain. Neurosci Lett 2004; 367: 273-277. (Pubitemid 39185844)
52. Alves da Costa C, Ancolio K, Checler F. Wild-type but not Parkinson's disease-related Ala53Thr-a-synuclein protect neuronal cells from apoptotic stimuli. J Biol Chem 2000; 275: 24065-24069. (Pubitemid 30624697)
53. El-Deiry W, Kern S, Pietenpol J, Kinzler K, Vogelstein B. Definition of a consensus binding site for p53. Nat Gen 1992; 1: 45-49.
54. Ginsberg D, Oren M, Yaniv M, Piette J. Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene 1990; 5: 1285-1290.
55. Alves da Costa C, Masliah E, Checler F. b-synuclein displays an antiapoptotic p53- dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase-3 activation. J Biol Chem 2003; 278: 37330-37335.
56. Le DA, Wu Y, Huang Z, Matsushita K, Plesnila N, Augustinack JC et al. Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 2002; 99: 15188-15193. (Pubitemid 35334631)
57. Zandy AJ, Lakhani S, Zheng T, Flavell RA, Bassnett S. Role of the executioner caspases during lens development. J Biol Chem 2005; 280: 30263-30272. (Pubitemid 41216206)